https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2025-03-04 / Cancers (Basel) 2025 Mar;17(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2025-03-04 / Cancers (Basel) 2025 Mar;17(5)2025-03-04 00:00:002025-03-17 07:36:12The Complexity of Malignant Glioma Treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-12-13 / Immunol Rev 2024 Jan;321(1):350-370
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-12-13 / Immunol Rev 2024 Jan;321(1):350-3702023-12-13 00:00:002023-12-13 00:00:00Decoding immunogenic cell death from a dendritic cell perspective
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-11-14 / Trends Cancer 2024 Jan;10(1):8-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-11-14 / Trends Cancer 2024 Jan;10(1):8-112023-11-14 00:00:002023-11-14 00:00:00Targeting immunogenic cell death for glioma immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-03-15 / Front Cell Infect Microbiol 2023;13:1142172
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-03-15 / Front Cell Infect Microbiol 2023;13:11421722023-03-15 00:00:002023-03-15 00:00:00Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-18 / Curr Oncol 2022 Sep;29(9):6700-6713
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-18 / Curr Oncol 2022 Sep;29(9):6700-67132022-09-18 00:00:002022-09-27 14:47:20Immunogenic Cell Death Role in Urothelial Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-08-24 / Pharmaceutics 2022 Aug;14(9)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-08-24 / Pharmaceutics 2022 Aug;14(9)2022-08-24 00:00:002022-08-24 00:00:00Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-19 / Genes Immun 2022 02;23(1):1-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-19 / Genes Immun 2022 02;23(1):1-112022-01-19 00:00:002022-01-19 00:00:00Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-01 / J Immunother Cancer 2020 03;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-01 / J Immunother Cancer 2020 03;8(1)2020-03-01 00:00:002022-09-29 14:17:36Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-26 / J Cell Mol Med 2020 04;24(7):4286-4297
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-26 / J Cell Mol Med 2020 04;24(7):4286-42972020-02-26 00:00:002022-09-29 14:03:50Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-29 / Front Oncol 2019;9:436
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-29 / Front Oncol 2019;9:4362019-05-29 00:00:002022-09-29 14:03:17STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
